Compare Incyte Corporation (INCY) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Microsoft — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Microsoft trades at $395.87 (market cap $2.99T). The key difference: Microsoft is far larger — about 129.4× Incyte Corporation's market cap, and Microsoft pays a 0.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MSFT | |
|---|---|---|
Market Cap | $23.11B | $2.99T |
Sector | Health | Technology |
52-Week High | $118.52 | $542.07 |
52-Week Low | $67.38 | $352.83 |
Enterprise Value | $19.13B | $2.97T |
Volume | — | 36,654,621 |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Microsoft trades at $397.75, up 1.0% with strong technical momentum as price approaches pivot point resistance at $398. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.27 versus $4.06, continuing a trend of earnings outperformance. Revenue growth accelerated to $281.72B in 2025 with net income margins expanding to 36.14%. Recent news highlights Microsoft's AI leadership through Azure and Copilot initiatives, though concerns about capital expenditures persist.
Microsoft presents a compelling investment case with 80% analyst buy ratings and a $546.70 consensus price target representing 37% upside. The company's AI positioning and cloud dominance support long-term growth, but risks include competitive pressures, high valuation multiples (P/E 23.96), and market volatility. Strong cash flow generation ($136.16B operating cash flow) and consistent dividend payments provide shareholder stability amid growth investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
